Table 3 Outcomes of interest in the e-nephro study
Populations | Outcomes of interest |
|---|---|
Primary outcome of interest | |
Population 1 | Cost-result ratio, where result is achievement of blood pressure (systolic ≤ 130 and diastolic ≤ 80 mmHg) and proteinuria (≤0.5 g/24 h or proteinuria/creatininuria ≤ 50 mg/mmol) recommended targets at V3 [33]. |
Populations 2 and 3 | Cost-result ratio, where result is the cumulative number of days of acute-care hospitalisation over the 1-year study period (from V1 to V3). |
Secondary outcomes of interest | |
Populations 1, 2, and 3 | Medication compliance measured by the French questionnaire by Girerd [34] |
Anxiety/depression level, measured with the Hospitalization Anxiety Depression Scale (HADS) [35, 36] | |
Quality-of-life, measured with the KDQoL V36 questionnaire [37] for populations 1, 2 and the ReTransQoL questionnaire [38] for population 3 | |
Intervention group of populations 1, 2, and 3 + healthcare practio-ners | Acceptability of the telemedicine system, measured with the French version of the Service User Technology Acceptability Questionnaire (WSD SUTAQ) for telemonitoring projects [39, 40]. The patient dropout rate from the telemedicine system will also be considered an indicator of the patient acceptability. |
Populations 1 and 3 | 1-year change in glomerular filtration rate measured with the MDRD formula [41] |
Population 3 | Number of planned nephrology outpatient visits actually performed, and the number of unplanned visits and hospitalisations over the 1-year study period |
Population 2 | Event-free survival at 1 year, an event being defined here as return to in-centre dialysis or hospitalisation |
Anaemia control, defined as achievement of haemoglobin, ferritin and coefficient of transferrin saturation recommended targets | |